FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study

British Journal of Cancer

Volumn 83, Issue 3, 2000, Pages 287-293

  Maisey, N R ^a   Webb, A ^a   Flux, G D ^a   Padhani, A ^a   Cunningham, D C ^a   Ott, R J ^a   Norman, A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOMYCIN C;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SYMPTOM; TUMOR VOLUME;

EID: 0033936579     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1166     Document Type: Article

References (33)

1. Ahlgren JD, Hill MA and Roberts I (1992) Pancreatic Cancer: Patterns, Diagnosis, and Approach to Treatment. Gastrointestinal Oncology. JB Lippincott, Philadelphia
2. Ahuja V, Coleman RE, Herndon J and Patz EF Jr (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83: 918-924
3. Bares R, Klever P, Hauptmann S, Hellwig D, Pass J, Cremerius U, Schumpelick V, Mittermayer C and Bull U (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79-86
4. Black RJ, Bray F, Ferlay J and Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1057-1107
5. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitahine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
6. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M and Ott R (1996) Non-invasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J Clin Oncol 14: 700-708
7. Flux GD (1995) Multimodality image registration and its application to the dosimetry of intralesional radionuclide therapy. University of London, London
8. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T and Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600
9. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F. Ziegler S, Reisser C, Doll J, Helus F and van Kaick G (1993) Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 34: 12-17
10. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotani R, Imamura M and Konishi J (1997) Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38: 1337-1344
11. Higashi T, Sakahara H, Torizuka T, Nakamoto Y, Kanamori S, Hiraoka M, Imamura M, Nishimura Y, Tamaki N, Konishi J (1999) Evaluation of intraoperative radiation therapy for unrespectable pancreatic cancer with FDG PET. J Nucl Med 40: 1424-1433
12. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ and Huijgens PC (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 34: 1706-1710
13. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J, Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C and Bull U (1995) Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 36: 229-235
14. Marsden PK, Ott RJ, Bateman JE, Cherry SR, Flower MA and Webb S (1989) The performance of a multiwire proportional chamber positron camera for clinical use. Phys Med Biol 34: 1043-1062
15. Miller AB, Hoogstraten B, Slaquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
16. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, Bergman J, Eronen E, Haaparanta M and Joensuu H (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38: 1907-1911
17. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, Okamura T, Kawabe J, Ochi H and Sowa M (1997) 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695-699
18. Nicolson M, Webb A, Cunningham D, Norman A, O'Brien M., Hill A and Hickish T (1995) Cisplatin and protracted venous infusion 5-fluorouracil (CF)-good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 6: 801-804
19. Okada J, Oonishi H, Yoshikawa K, Imaseki K, Uno K, Itami J and Arimizu N (1994a) FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 8: 109-113
20. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K and Arimizu N (1994b) FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8: 187-191
21. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, Asano T and Ryu M (1992) Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment [see comments]. J Nucl Med 33: 333-339
22. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K and Nakajima N (1998) Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 82: 2227-2234
23. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882-885
24. Price P and Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?. The EC PET Oncology Concerted Action and the EORTC PET Study Group. European Journal of Cancer 31A: 1924-1927
25. Prott FJ, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O, Potter R, Sulkowski U, Rube C, Berns T and Willich N (1997) Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75: 597-601
26. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F and Beger HG (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38: 1344-1348
27. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T and Foidart Willems J (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23: 1641-1674
28. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
29. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG and Reske SN (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments]. Radiology 195: 339-344
30. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23: 1409-1415
31. Wahl R, Cody R, Zasadny K and al e (1991) Active breast cancer chemohormonotherapy sequentially assessed by FDG-PET: Early metabolic decrements precede tumour shrinkage. J Nucl Med 32: 982
32. Wittenburg J, Simeone J and Ferrucci J (1982) Non-focal enlargement in pancreatic carcinoma. Radiology 144: 131-135
33. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V and Buell U (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678-682